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Background: Indications for surgery during pregnancy have increased. Specifically
fetal interventions have increased from conditions that were considered lethal like
twin-twin transfusion syndrome and severe fetal anemia to non-lethal conditions like
myelomeningocele. The optimal anesthetic agent for in utero surgery is yet to be
determined. Success of the procedure is often dictated by the efficacy of the anesthetic
to immobilize the fetus without over-sedating mom. Remifentanil is used as preferred
agent due to its short half-life however pharmacokinetics in pregnancy is unknown.
Objective: To determine the pharmacokinetic parameters of remifentanil in a
mid-trimester pregnant patient population undergoing fetal intervention.
Study Design: A validated liquid chromatography assay with ultraviolet absorbance was
employed to estimate maternal serum remifentanil levels. Blood samples were obtained
at baseline and at selected time points: 5, 15, 30, 45, 60 min after the beginning of the
remifentanil infusion and at 15, 30, and 60 min post end of infusion.
Results: Ten pregnant patients were enrolled in the study however only eight
patients had sampling obtained at all time points. The mean gestational age was
22.2 (±2.7) weeks, maternal age was 27.8 (±5.1) years and body mass index was
29.6 (±6.3). After receiving a continuous infusion of remifentanil, mean total dose
was 975.3 µg, Cmin was 2.0 ng/mL and Cmax was 8.4 ng/mL. A two-compartment
model best described the plasma remifentanil data. Mean pharmacokinetic parameters
were: volume of distribution (Vd =c) 124.6 L (16.2–530.8 L), maternal remifentanil
total clearance (Clt) = 170.7 L/h (17.7–486.9 L/h), and half-life (t )½ = 0.6 h (0.2–
0.9 h). The maternal remifentanil area under the curve (AUC) ranged from 2.7 to
21.7 µg/L∗h. The mean alpha-acidic glycoprotein was 124.8 mg/dL (81.3–149.8).
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Conclusion: The pharmacokinetic profile of remifentanil in pregnant women is similar to
previously reported general population profiles. This data did provide potential rationale
for the clinical observations why when remifentanil is dosed based on non-pregnant
guidelines, it did not uniformly provide adequate fetal immobilization as per anecdotal
perception of operating fetal surgeons. These findings are important for the development
of further clinical studies to optimize dosing for surgery during pregnancy including the
estimation of placental transfer and total fetal exposure.
Keywords: fetal anesthesia, pregnancy pharmacokinetics, remifentanil, twin-twin transfusion syndrome
INTRODUCTION
Despite the increasing popularity of specific anesthetic agents
used for fetal intervention procedures such as remifentanil, very
little information about their pharmacological and toxicological
profiles in the maternal-fetal population exist (Dershwitz et al.,
1995). Limited information exists about the long-term effects of
fetal exposure to anesthetics, and yet, based on limited animal
and human studies, a great public concern has been raised
about the potential long-term neurotoxic effects of anesthetic
exposure in early life (Loepke and Soriano, 2008). Fetal life
is a period of active brain development, with a hypothesized
greater susceptibility to environmental and pharmacologic
insults (Palanisamy, 2012). The indications for fetal surgery
have increased in recent years, with an expected increase in
the number of procedures to be performed in the future
(Deprest et al., 2010). Given the significant maternal and
fetal morbidity inherent to fetal surgery, these procedures are
reserved for conditions that are either lethal or associated
with significant long-term disability, such as twin-to-twin
transfusion syndrome, congenital diaphragmatic hernia and
myelomeningocele. Additionally, fetal exposure to anesthetic
agents can occur at any time during pregnancy for a maternal
complication requiring operative intervention such as acute
appendicitis.
Remifentanil is a category C potent ultra-short acting
synthetic opioid drug. It is FDA approved for sedation and
analgesia in both adults and children. It is usually combined
with other medications for induction andmaintenance of general
anesthesia and is typically administered intravenously as a bolus
or as a continuous infusion. Remifentanil is metabolized via
rapid hydrolysis by non-specific plasma and tissue esterases. The
terminal half-life is 10–21 min (Westmoreland et al., 1993).
When compared with other anesthetic agents such as
diazepam for fetal intervention procedures, remifentanil
produces maternal sedation and analgesia as well as fetal
immobilization in a more rapid and pronounced manner.
This has the potential to decrease the total surgical time and
subsequently the length of fetal exposure to anesthetic agents
(Van De Velde et al., 2005). Evidence also shows that remifentanil
may have neuro-protective and other cell protective properties
(Fodale et al., 2008; Jeong et al., 2012). However, the optimal dose
needed to provide adequate fetal sedation is not clearly studied.
Anecdotal experience has observed that when dosing is based
on non-pregnant studies, it unfortunately does not uniformly
provide adequate fetal immobilization. This led to the current
study to determine the pharmacokinetic profile of this drug in
pregnancy. The primary objective of this study was to define the
pharmacokinetic (PK) parameters of remifentanil in a pregnant
patient population in mid-gestation. A secondary objective of
the study was to evaluate the alpha acidic glycoprotein (AAG)
levels on remifentanil pharmacokinetics. AAG is a serum
“stress plasma protein” with a short 7 to 10 day half-life that
readily binds to medications. Remifentanil is reported to have
greater than 80% plasma protein binding (PPB), with over
75% specifically to AAG, however the impact of gestational
stress, such as twin transfusion syndrome, on AAG levels has
not been evaluated. This basic knowledge of the maternal
pharmacokinetics of remifentanil and better understanding of
the impact of gestational stress on AAG levels will open the
doors for further toxicological and fetal (PK/PD) research.
MATERIALS AND METHODS
Patient and Study Design
Patient enrollment was approved by the institutional review
board (IRB) of the University of Texas Health Science Center at
Houston and Children’s Memorial Hermann Hospital, Houston,
TX. The population selected included patients undergoing laser
photocoagulation of placental anastomoses for twin-to-twin
transfusion syndrome (TTTS). Patients underwent standardized
ultrasound evaluation and counseling in order to determine if
they were candidates for fetal intervention for TTTS. Only after
they had been deemed appropriate surgical candidates by the
faculty of The Fetal Center were they offered enrollment and
consented to participate in the study.
Remifentanil Infusion
The remifentanil infusion was initiated at 0.05–0.08
mcg·kg−1·min−1 just prior to surgical procedure upon the
transfer of the patient to the operating room table. The infusion
was initiated with a higher dose followed by continuous
intravenous infusion adjusting the rate based upon the patient
and the fetus’s sedation level and physiological response. The
initial infusion rate and any changes made by the anesthesiologist
or surgeon in order to attain optimal operative conditions were
documented on the data collection sheet.
An additional intravenous catheter was placed in the
contralateral arm then the one used for the remifentanil infusion
for pharmacokinetic (PK) sampling. Plasma concentrations of
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remifentanil were obtained at baseline and at selected time
points: 5, 15, 30, 45, 60min after the beginning of the remifentanil
infusion and at 15, 30, and 60min post end of infusion (Figure 1).
Due to limitations set by the IRB for the number of samples that
can be obtained from a pregnant patient, the above time points
were chosen.
An initial baseline sample of 12mL was drawn; 6mL used
for PK and the remaining 6mL was used for determining the
AAG levels. All the other samples were 6mL. The intravenous
catheter was flushed with normal saline after each blood sample
collection to help prevent clotting thus, the initial 2mL of blood
was discarded prior to each PK sample being drawn. The samples
were placed on ice, transported to the analytical core laboratory
and processed within 15 min of collection. The collection tube
was centrifuged under refrigeration (4◦C) 1000 × G for 10 min
to separate the cellular elements from the plasma. Maternal
plasma samples were then stored at −80◦C until the time of
analysis.
Remifentanil Sample Analysis
Remifentanil concentrations were quantified by validated high
pressure liquid chromatography (HPLC) assay according to
parameters described in the CDER Guidance for Industry
Bioanalytical Assay Method Validation (Guidance for Industry:
Bioanalytical Method Assay Validation, 2001). Remifentanil
was isolated from maternal plasma samples by solid phase
extraction after the addition of 10µL of fentanyl 10µg/mL as
the internal standard. Liquid chromatographic separation was
achieved by isocratic mobile phase: the mobile phase consisted
of a composition of 60% of the following mixture: acetonitrile:
methanol: 50mM potassium phosphate buffer, pH3: water
(180:120:48:652), and 40% methanol adjusted pH 7.2 with flow
rate 1 mL/min with a elution on a Phenomenex PhenoSphere
C1, 150 × 4.6mm, 5 µm particle size packing analytical column
(Phenomenex, Torrance, CA). The remifentanil peak eluted
at 9.20 ± 0.2min and fentanyl retention time was 11.50 ±
0.2min identified by photodiode array detector at a wavelength
of 210 nm. The remifentanil assay was found to be linear
over 2–100 ng/mL with a correlation coefficient (r) of 0.997.
The coefficient of variation for the remifentanil assay ranged
from 0.16 to 14.9%. The alpha1-acidic glycoprotein (AAG)
FIGURE 1 | Sample draw timeline. The figure shows all time points at which
blood samples were drawn.
was determined using the Quantikine ELISA technique (R&D
systems, Inc. Minneapolis, MN, USA).
Pharmacokinetic Analysis
The plasma concentration time data was fit using ADAPT II
Software Version 4.0. (BMRS, University of Southern California,
Los Angeles, CA, USA) to determine optimal PK model to
describe the data (D’argenio and Schumitzky, 1979). Model
discrimination was based on the Aikaike inspection criteria
(AIC), Schwartz, weighted sum of squares, sum of squares and
linear correlation (R2) as well as visual inspection of the data fit.
Systemic exposure (AUC) was calculated: AUC (µg·L−1·h−1) =
[total dose (µg)/total clearance (L/h)].
RESULTS
A total of 10 pregnant patients were enrolled in the study however
only eight patients had complete sampling; these eight patients
comprised the study population. The mean gestational age was
22.2 (±2.7) weeks. The mean maternal age was 27.8 (±5.1) years
and BMI was 29.6 (±6.3). Five of the patients were Hispanic and
3 were Caucasian (Table 1). The mean Cmin = 2.0 ng/mL and
the mean Cmax = 8.4 ng/mL after receiving continuous infusion
of remifentanil with a mean total dose of 975.3 mcg. The mean
remifentanil concentration per minute was 12.6 ± 7.8 ng/ml
(Table 2).
A two-compartment model best described the plasma
remifentanil data. Mean PK parameters were: volume
of distribution (Vdc) = 124.6 L (16.2–530.8 L), maternal
remifentanil total clearance (Clt) was 170.7 L/h (17.7–486.9 L/h),
and half-life (t½) was 0.6 h (0.2–0.9 h). Thematernal remifentanil
AUC ranged from 2.7 to 21.7µg·L−1·h−1 (Table 2). The mean
AAG was 124.8mg/dL (81.3–149.8mg/dL) in these pregnant
patients.
DISCUSSION
The pharmacokinetics of remifentanil in normal healthy non-
pregnant adults has been shown to be similar in both genders
(Egan, 1995; Minto et al., 1997; Scott and Perry, 2005). The
data from this study suggested that the PK profile in pregnant
women is similar to other healthy non-pregnant women with
a few notable differences. The mean volume of distribution in
this study was 124.6 L (±170.2), which is higher than normal
healthy individuals (25–40 L) (Westmoreland et al., 1993).
This was approximately a 3.3-fold increase in the volume of
distribution, which is not unexpected in pregnancy. There is a
40–50% increase in the maternal blood volume in pregnancy
which starts early in the first trimester and peaks at around 32
weeks gestation (Hytten and Paintin, 1963). Thus, this increased
maternal circulating volume contributes to the greater volume
of distribution noted in the current study in pregnant patients.
This might be an attributing factor to the clinical observation
of delay in fetal immobilization that had prompted this study.
Previous studies have shown a significant amount of transfer of
remifentanil across the placenta (Welzing et al., 2011; Heesen
et al., 2013). However, there is also rapid metabolism and
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TABLE 1 | Demographics and infusion data.
Patient Age Gestational age
(weeks)
Race Gravity and parity at
the time of evaluation
TTTS
stage
BMI Starting infusion
(mcg·kg−1·h−1)
Starting infusion
dose (mcg/h)
Duration of
infusion (min)
1 28 21 White G2P1 III 31 0.3 1480 85
2 30 26 White G2P1 I 24 0.08 396 82
3 21 25.7 White G2P1 IV 43 0.12 792 73
4 24 21.4 Hispanic G4P3 I 21 0.2 672 81
5 32 18.9 White G2P0 III 30 0.5 2280 84
6 33 21.4 Hispanic G6P4 II 30 0.05 241 62
7 33 19.4 White G3P1 II 29 0.1 366 67
8 21 23.6 Hispanic G2P1 II 29 0.1 438 70
Demographics and infusion data for each patient in the study.
TABLE 2 | Pharmacokinetic results.
Remifentanil
Cmin (ng/mL)
Remifentanil
Cmax (ng/mL)
Mean concentration
during infusion
(ng/mL)
Maternal total
clearance
Clt (L/h)
Volume of
Distribution
Vdc (L)
Mean Half-
life (h)
AUC
(µg·L−1·h−1)
AAG
level (mg/dL)
Mean 2.0 8.4 4.8 170.7 124.6 0.6 10.6 124.8
Standard
deviation
1.3 5.0 2.7 185.2 170.2 0.2 6.7 24.2
CV% 67.4 60.2 57.8 108.5 136.7 43.4 63.7 19.4
Pharmacokinetic results with mean, standard deviation, and coefficient of variation (CV%).
redistribution of remifentanil Kan et al. (1998). have shown an
umbilical vein: maternal serum (UV:MA) ratio of 0.88 ± 0.78
and an umbilical artery: umbilical vein ratio of 0.29 ± 0.07. This
was similarly demonstrated in a randomized trial by Ngan Kee
et al. (2006) where the UV:MA ratio was 0.73 ± 0.17. During
the current PK study there was a concurrent pharmacokinetic
study in pregnant women undergoing intrauterine transfusions
that also received sedation with remifentanil that observed
a similar transfer fraction (UV:MA) of 0.64 ± 0.52. These
studies would indicate that transplacental transfer/distribution
of remifentanil into the fetal compartment may also contribute
to the greater volume of distribution noted in the current
study.
The maternal remifentanil clearance in our study was 170.7
L/h (±185.2), which is lower than the clearance previously
reported in non-pregnant women (250–300 L/h) (Westmoreland
et al., 1993). The half-life in our study was 0.6 h (±0.2) as
compared to non-pregnant women where it ranges from 0.2 to
0.4 h (Westmoreland et al., 1993). We therefore found a 1.8 fold
decrease in the remifentanil clearance, which would explain the
increase in the half-life by about 1.5-fold. Typically in pregnancy
the renal blood flow and the glomerular filtration rate (GFR) are
increased by approximately 50% (Dunlop, 1981). This increase in
the GFR results in an increase in the elimination of medications
that are cleared by renal excretion and a corresponding shorter
half-lives (Pacheco and Hankins, 2013). However, remifentanil is
predominantly metabolized by non-specific circulating esterases
to an acid metabolite GI-90291 (Westmoreland et al., 1993).
This metabolite is excreted through the kidney. The clearance
of remifentanil is therefore not affected directly by the maternal
renal function.
The decrease in clearance could be related to the increase
in the AAG levels noted in the current study as compared to
the non-pregnant population. The mean level of 125 mg/dL
observed in these patients was nearly two-fold higher than the
mean level of 62.6 mg/dL previously reported by Chu et al. (1981)
Approximately 70% of remifentanil is bound to plasma proteins;
one third to albumin but most of it, greater than two-thirds,
is bound to AAG decreasing its free-fraction available for drug
activity. Certain plasma proteins like albumin are decreased in
pregnancy, while others like sex hormone binding globulins are
increased (Pacheco and Hankins, 2013). These changes in the
protein concentrations are important in determining the drug
response (Wood and Wood, 1981). AAG is a physiological stress
protein, hence in conditions associated with more physiological
stress, higher levels of AAG will be observed. For example,
Chu et al. (1981) did not find any difference in the AAG
levels in uncomplicated pregnancies when compared to non-
pregnant women (62.6 ± 18.8mg/dL). However, they did find
that pregnancies complicated by acute or chronic inflammation
resulted in an increase in AAG levels (Chu et al., 1981). The
current study found that the AAG was elevated (124.8 mg/dL ±
24.2). Although the study patients did not have any significant
medical history, their pregnancies were complicated by the need
for fetal surgery. The effects of fetal surgery on maternal stress
have not been studied, however any surgery would appear to
cause significant psychological stress. Coussons-Read et al. (2007)
demonstrated an increase in the pro-inflammatory cytokines
Frontiers in Pharmacology | www.frontiersin.org 4 January 2017 | Volume 8 | Article 11
Smith et al. Remifentanil Pharmacokinetics in Pregnancy
and acute phase reactants in cases of increased prenatal stress.
The increased AAG concentration results in an increase in the
amount of protein-bound of remifentanil, decreasing the free
fraction of the active remifentanil. Hence the elevated AAG levels
may also have contributed to the clinical observations of delay
fetal immobilization when pregnant women are dosed based
on non-pregnant dosing guidelines. In addition, subsequently
a two-fold decrease in its clearance that was observed in
this study. As a result of the decreased clearance and longer
elimination half-life, a more prolonged interval may be necessary
to reach a steady state in the pregnant woman. The delay
in reaching steady state is another factor have contributed to
the clinical observations of delay fetal immobilization when
pregnant women are dosed based on non-pregnant dosing
guidelines.
This study is limited by its small sample size.While enrolled 10
pregnant patients and were able to obtain adequate samples from
8 women. This is a prospective study of pregnant women in their
second trimester undergoing a fetal procedure and we were able
to obtain pharmacokinetic studies in these women, which have
enhanced our understanding of remifentanil effects in pregnant
women.
In conclusion, the PK profile of remifentanil in pregnant
and non-pregnant women was similar but with differences in
volume of distribution, clearance, half-life and AAG levels.
While limited by a small sample size, this data did provide
some potential rationale for the clinical observations why when
remifentanil is dosed based on non-pregnant guidelines, it does
not uniformly provide adequate fetal immobilization hence
higher remifentanil doses may be required to achieve adequate
fetal immobilization. Clinically these higher remifentanil doses
may not have a significant impact on patient outcomes given
the benefits of remifentanil in obtaining adequate fetal analgesia
and its rapid clearance from the fetal circulation. These findings
are important for the development of further clinical studies
to optimize dosing for surgery during pregnancy including the
estimation of placental transfer and potential total fetal exposure.
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